Ho Chi Minh City, Vietnam – October 8, 2025 — Gene Solutions is honored to contribute to the IASLC Asia Conference on Lung Cancer (ACLC) 2025 with the presentation of five scientific abstracts, underscoring our continued commitment to innovation in lung cancer care.
The International Association for the Study of Lung Cancer (IASLC) is the global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Its Asia Conference on Lung Cancer (ACLC) is a leading Asia-Pacific forum that convenes clinicians and scientists to share advances in prevention, diagnosis, and treatment of lung cancer. This year’s conference takes place October 9–11, 2025, at Hotel Equatorial, Ho Chi Minh City, Vietnam, and will address key regional challenges such as biomarker testing, early detection, and equitable access to targeted therapies and immunotherapy.
Our presentations span the breadth of prospective research and real-world clinical utility, showcasing how we integrate multi-omics and AI-enabled analytics from early cancer detection to precision treatment selection and longitudinal monitoring in lung cancer.
List of Poster Presentations:
Friday, October 10, 2025 | 5:00 PM – 6:00 PM
- PP01.56
Direct Comparison of Tumor-Informed and Tumor-Agnostic ctDNA Assays in Non-Small Cell Lung Cancer
Presenter: Van-Anh Nguyen Hoang - PP01.59
Circulating Tumor DNA Dynamics to Predict Response to Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: An Interim Report
Presenter: Tu Nguyen - PP01.60
Integrating Tumor Comprehensive Genomic and Transcriptomic Profiling with Plasma ctDNA Monitoring to Maximize Clinical Benefits in Advanced Lung Cancer
Presenter: Nam HB Tran - PP01.65
Prospective Validation of a Cost-Effective Multimodal Cell-Free DNA Assay for Early Lung Cancer Detection in Symptomatic and High-Risk Cohorts: An Interim Report
Presenter: Van Thien Chi Nguyen - PP01.68
Clinical Utility of a Multi-Omic, cfDNA-Based Assay in the Early Detection of Lung Cancer: A Case Series
Presenter: Hong-Dang Luu Nguyen
Conference Highlight
In an additional highlight of the event, Professor Feng-Ming (Spring) Kong, Conference Chair, will deliver a lecture on AI in Lung Cancer Drug Development and Treatment Response Assessment at session ES13, Saturday, October 11, 2025. Her pioneering work in AI and personalized immunotherapy has strengthened regional collaboration for lung cancer, as previously shared at K-CONNECT APAC 2025 and Best of ASCO Hong Kong 2025.
About Gene Solutions
Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology – from early detection to real-time treatment monitoring.
